Martin MacKay

Dr. Martin W.
MacKay is a Chairman at Rallybio Corp., a Chairman at Charles River Laboratories International, Inc., a Chief Executive Officer at Calyx Group Ltd. (Ireland), a Chief Executive Officer & Director at Rallybio Holdings LLC and an Independent Director at Charles River Laboratories, Inc. He is on the Board of Directors at Kailera Therapeutics, Inc., Rallybio Holdings LLC and Charles River Laboratories, Inc. Dr. MacKay was previously employed as an Independent Director by Springworks Therapeutics, Inc., an Independent Director by 5:01 Acquisition Corp., an Independent Director by Novo Nordisk A/S, a Senior Advisor by New Leaf Venture Partners LLC, a Chairman by Rallybio LLC, a Global Head-Research & Development by Alexion Pharmaceuticals, Inc., a Chief Executive Officer & Director by Neverfail, Inc., a President-Global Research & Development by AstraZeneca PLC, a President by Pfizer (St. Louis), a Senior Vice President-Worldwide Development by Pfizer Inc., a Head-Molecular & Cell Biology by CNS Research Institute P.C., a Head-Drug Preformulation & Delivery by Ciba-Geigy Pharmaceuticals, a Principal by Accenture LLC, a Head-Drug Preformulation & Delivery by BASF Performance Products Ltd. (United Kingdom), a Principal by Beecham Pharmaceuticals (UK), a Chief Executive Officer & Director by Neverfail Ltd., a Director-Business Development by NorthgateArinso, Inc., a Principal by PeopleSoft USA, Inc., an Operations Director by The Dun & Bradstreet Corp., a Chief Executive Officer by Vecta Software Corp.
Ltd., and a Vice President-International by VeriSign, Inc. He also served on the board at Encysive Pharmaceuticals, Inc. He received his undergraduate degree from Heriot-Watt University and a doctorate degree from The University of Edinburgh.